Agilent, Florida International Developing Screening Methods for Designer Drugs | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies today announced a collaboration with Florida International University to develop methods for the identification and characterization of designer drugs.

Agilent is working with FIU's department of chemistry and biochemistry and its International Forensics Research Institute and is currently focused on developing and validating methods for rapid forensic screening and analysis to expand the capabilities of drug screening techniques using immunoassays, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.